Repligen is acquiring Avitide, a manufacturer of affinity ligands for the biopharmaceutical industry. The company expects Avitide to generate $10 million in revenue in 2022. The deal is valued at $150 million. Half of that amount will be paid in cash and the other half in Repligen stock. The deal is scheduled to close in Q3 2021.
Repligen is acquiring Avitide, a manufacturer of affinity ligands for the biopharmaceutical industry. The company expects Avitide to generate $10 million in revenue in 2022. The deal is valued at $150 million. Half of that amount will be paid in cash and the other half in Repligen stock. The deal is scheduled to close in Q3 2021. 
repligen.q4ir.com
English (US) 